Can we offer more for cognitive impairment in patients with chronic hepatitis C?

Ugo NOCENTINI

doi:10.1590/0004-282X20200055

Arquivos de Neuro-Psiquiatria, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2020; 78(06): 319-320
DOI: 10.1590/0004-282X20200055

EDITORIAL

Can we offer more for cognitive impairment in patients with chronic hepatitis C?

É possível oferecer algo a mais para pacientes com hepatite C crônica com comprometimento cognitivo?

Authors

Ugo NOCENTINI

¹Università di Roma “Tor Vergata”, Dipartimento di Scienze Cliniche e Medicina Traslazionale, Roma, Italia.

²Fondazione “Santa Lucia” Istituto di Ricovero e Cura a Carattere Scientifico, Roma, Italia.

Abstract

Volltext

Referenzen

References
1 Thomas DL. Global elimination of chronic hepatitis. N Engl J Med. 2019 May;380(21):2041-50. https://doi.org/10.1056/nejmra1810477
2 Mathew S, Faheem M, Ibrahim SM, Iqbal W, Rauff B, Kaneez F, et al. Hepatitis C virus and neurological damage. World J Hepatol. 2016;8(12):545-56. https://doi.org/10.4254/wjh.v8.i12.545
3 Iriana S, Curry MP, Afdhal NH. Neurologic manifestations of hepatitis C virus infection. Clin Liver Dis. 2017 Aug;21(3):535-42. https://doi.org/10.1016/j.cld.2017.03.008
4 Yarlott L, Heald E, Forton D. Hepatitis C virus infection, and neurological and psychiatric disorders - A review. J Adv Res. 2017 Mar;8(2):139-48. https://doi.org/10.1016/j.jare.2016.09.005
5 Di Filippo M, Portaccio E, Mancini A, Calabresi P. Multiple sclerosis and cognition: synaptic failure and network dysfunction. Nat Rev Neurosci. 2018 Oct;19(10):599-609. https://doi.org/10.1038/s41583-018-0053-9
6 Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015 Jun;16(6):358-72. https://doi.org/1010.1038/nrn3880
7 Saferding V, Blüml S. Innate immunity as the trigger of systemic autoimmune diseases. J Autoimmun. 2020 Jun;110:102382. https://doi.org/10.1016/j.jaut.2019.102382
8 Machado MO, Oriolo G, Bortolato B, Köhler CA, Maes M, Solmi M, et al. Biological mechanisms of depression following treatment with interferon for chronic hepatitis C: a critical systematic review. J Affect Disord. 2017 Feb;209:235-45. https://doi.org/10.1016/j.jad.2016.11.039
9 Belvederi Murri M, Cecere AC, Masotti M, Sammito G, la Marca A, Torres GV, et al. Biopsychosocial predictors of interferon-related depression in patients with hepatitis C. Asian J Psychiatr. 2017;26:24-8. https://doi.org/10.1016/j.ajp.2017.01.001
10 Gascon MRP, Benute GRG, Macedo EC, Capitão CG, Bermudez JEV, Smid J, et al. Cognitive assessment in patients with Hepatitis C submitted to treatment with Sofosbuvir and Simeprevir or Daclatasvir. Arq Neuro-Psiquiatr. In press.
11 Schwartz CE, Michael W, Zhang J, Rapkin BD, Sprangers MAG. Assessing reserve-building pursuits and person characteristics: psychometric validation of the reserve-building measure. Qual Life Res. 2018 Feb;27(2):423-36. https://doi.org/10.1007/s11136-017-1694-2